About Hereditary Hemorrhagic Telangiectasia (HHT) ‍HHT is a rare disease that affects more than 150,000 people in the U.S. and EU, and for which there are currently no approved therapies.

About Hereditary Hemorrhagic Telangiectasia (HHT) Advertisement ‍HHT is a rare disease that affects more than 150,000 people in the U.S. and EU, and for which there are currently no approved therapies ...

Study conducted in partnership with Cure HHT will inform future clinical trials and treatment options for people living with HHT Company recently progressed DIAG723 into IND-enabling studies for ...

WATERTOWN, Mass. , March 04, 2025 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company focused on correcting dysregulated signaling with multispecific antibodies that address the ...

- HHT costs are higher than other expensive-to-treat rare diseases and exceedingly higher in people who are anemic and require hematological support, highlighting the need for new treatment options ...

BASEL, Switzerland, Nov. 18, 2024 /PRNewswire/ -- Vaderis Therapeutics AG (Vaderis), a clinical stage biotechnology company focusing on treatments for rare diseases associated with vascular ...

Video laryngoscopy showed a higher first-attempt success rate than direct laryngoscopy for emergency tracheal intubation in critically ill patients under hospital settings, found a new trial.

HealthDay News — For patients with hereditary hemorrhagic telangiectasia (HHT), pomalidomide yields a significant reduction in epistaxis severity, according to a study published in the September ...

‘#Hereditary_hemorrhagic_telangiectasia (HHT) is a rare #bleeding disorder that affects more than 1 in 5,000 individuals globally. #medindia ’ A single patient sparked this trial.